286 related articles for article (PubMed ID: 24438203)
1. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
Aberer W; Maurer M; Reshef A; Longhurst H; Kivity S; Bygum A; Caballero T; Bloom B; Nair N; Malbrán A
Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203
[TBL] [Abstract][Full Text] [Related]
2. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
[TBL] [Abstract][Full Text] [Related]
3. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
[TBL] [Abstract][Full Text] [Related]
4. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
[TBL] [Abstract][Full Text] [Related]
8. Icatibant for the treatment of hereditary angioedema.
Cole SW; Lundquist LM
Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
[TBL] [Abstract][Full Text] [Related]
10. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
Longhurst HJ; Aberer W; Bouillet L; Caballero T; Maurer M; Fabien V; Zanichelli A;
Eur J Emerg Med; 2016 Jun; 23(3):224-7. PubMed ID: 27116379
[TBL] [Abstract][Full Text] [Related]
11. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
[TBL] [Abstract][Full Text] [Related]
12. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
[TBL] [Abstract][Full Text] [Related]
13. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
14. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
[TBL] [Abstract][Full Text] [Related]
15. Icatibant as acute treatment for hereditary angioedema in adults.
Farkas H
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
[TBL] [Abstract][Full Text] [Related]
16. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.
Longhurst HJ; Aberer W; Bouillet L; Caballero T; Fabien V; Zanichelli A; Maurer M;
Allergy Asthma Proc; 2015; 36(5):399-406. PubMed ID: 26314822
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.
Baş M
Expert Rev Clin Immunol; 2012 Nov; 8(8):707-17. PubMed ID: 23167682
[TBL] [Abstract][Full Text] [Related]
18. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
Prescrire Int; 2010 Nov; 19(110):245-7. PubMed ID: 21284353
[TBL] [Abstract][Full Text] [Related]
19. Icatibant in hereditary angioedema: news and challenges.
Bouillet L
Expert Rev Clin Immunol; 2011 May; 7(3):267-72. PubMed ID: 21595592
[TBL] [Abstract][Full Text] [Related]
20. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
